Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$495.00
|
|
Trading Report for (BMY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bristol-Myers Squibb Co. Reaffirms FY 2012 EPS Guidance
Bristol-Myers Squibb Co. announced that for fiscal 2012, it confirms GAAP and non-GAAP EPS guidance range of $1.90 to $2.00. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $1.97 for fiscal 2012.
Latest Developments for Bristol-Myers Squibb Co
- Bristol-Myers Squibb Co Receives US FDA sNDA Approval For Use Of SUSTIVA (efavirenz) In HIV-1 Infected Pediatric Patients
- Bristol-Myers Squibb Co Reaffirms FY 2013 EPS Guidance
- Bristol-Myers Squibb Co's and Sanofi SA's Plavix to Be Investigated by U.S. Department of Justice-Reuters
- UK Cost Agency Rejects Drugs From Bristol-Myers Squibb Co, Roche Holding AG And AstraZeneca PLC-Reuters
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters